Skip to main content
NewslettersWatchlist

Engene Holdings Inc(ENGN-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low7.43
Day High7.97
Open:7.51
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Newswire.ca
enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting
Newswire.ca
engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical Development
Newswire.ca
/C O R R E C T I O N -- enGene Inc./
Newswire.ca
enGene Announces Hiring of Dr. Raj Pruthi as Senior Vice President, Urologic Oncology and Clinical Development
Newswire.ca
enGene Reports First Quarter 2024 Financial Results and Recent Corporate Progress
Newswire.ca
enGene To Present at the Leerink Partners Global Biopharma Conference
The Globe and Mail
Engene stock skyrockets as Montreal gene therapy developer raises $200-million on Nasdaq
Newswire.ca
enGene Announces Oversubscribed $200 Million Private Placement Financing
Newswire.ca
enGene Announces Leadership Succession Plan
Newswire.ca
enGene Appoints Lee Giguere as Chief Legal Officer and Corporate Secretary
Newswire.ca
enGene Reports Full Year 2023 Financial Results and Recent Operational Progress
Newswire.ca
enGene Announces Expanded $50 Million Debt Facility with Hercules Capital
Newswire.ca
enGene Appoints Lota S. Zoth, CPA, as Member of the Board of Directors
Newswire.ca
enGene Appoints Ryan Daws as Chief Financial Officer
ACCESSWIRE
Lumira Ventures Portfolio Company enGene (Nasdaq:ENGN) Debuts as Publicly Traded Genetic Medicines Company

Profile

enGene Holdings Inc. is a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues. enGene Holdings Inc., formerly known as Forbion European Acquisition Corp., is based in MONTREAL.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright ยฉ 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright ยฉ 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.